Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy

Annals of Surgical Oncology

Volumn 11, Issue 5, 2004, Pages 465-475

  Eisenberg, Burton L ^a,c   Judson, Ian ^b  

^a NORRIS COTTON CANCER CENTER   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Gastrointestinal stromal tumor; Imatinib; KIT; Signal; Surgery; Transduction inhibitor

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADJUVANT THERAPY; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEMOPERITONEUM; HUMAN; METASTASIS; MUTATION; NAUSEA; OUTCOMES RESEARCH; POSITRON EMISSION TOMOGRAPHY; RASH; REVIEW; SURVIVAL RATE; SURVIVAL TIME; VOMITING; ADJUVANT CHEMOTHERAPY; GASTROINTESTINAL TUMOR; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; PROGNOSIS; RISK ASSESSMENT; STROMA CELL; SURVIVAL;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PATIENT SELECTION; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RISK ASSESSMENT; STROMAL CELLS; SURVIVAL ANALYSIS;

EID: 3242744597     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2004.09.011     Document Type: Review

References (88)

1. Walsh NM, Bodurtha A. Auerbach's myenteric plexus. A possible site of origin for gastrointestinal stromal tumors in von Recklinghausen's neurofibromatosis. Arch Pathol Lab Med 1990;114:522-5.
2. Kindblom LG, Remotti HE, Aldenberg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-69.
3. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11:728-34.
4. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
5. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983;7:507-19.
6. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-5.
7. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21.
8. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12.
9. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65.
10. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4.
11. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
12. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32.
13. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.
14. van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EOERTIC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38(Suppl 5):S83-7.
15. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
16. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
17. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002;38(Suppl 5):S37-8.
18. Sturgeon C, Chejfec G, Espat NJ. Gastrointestinal stromal tumors: a spectrum of disease. Surg Oncol 2003;12:21-6.
19. Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg 1996;33:817-72.
20. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001;8:50-9.
21. Nishida T, Hirota SI. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000;15:1293-301.
22. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000;13:1134-42.
23. Kindblom L-G, Meis-Kindblom J, Bümming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST) - a population-based study of 600 cases. Ann Oncol 2002;13(Suppl 5):157.
24. Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2001;2:485-91.
25. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002;38(Suppl 5):S39-51.
26. Bauer S, Corless CL, Heinrich MC. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 2003;51:261-5.
27. Sabah M, Leader M, Kay E. The problem with KIT: clinical implications and practical difficulties with CD117 immunostaining. Appl Immunohistochem Mol Morphol 2003;11:56-61.
28. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000;7:705-12.
29. DeMatteo RP, Maki RG, Antonescu C, Brennan MF. Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Curr Probl Surg 2003;40:144-93.
30. Lehnert T. Gastrointestinal sarcoma (GIST) - a review of surgical management. Ann Chir Gynaecol 1998;87:297-305.
31. Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus. A clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001;25:1121-33.
32. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002;33:669-76.
33. Judson I. Gastrointestinal stromal tumours (GIST): biology and treatment. Ann Oncol 2002;13(Suppl 4):287-9.
34. Emory TS, O'Leary TJ. Prognosis and surveillance of gastrointestinal stromal/smooth muscle tumors. Ann Chir Gynaecol 1998;87:306-10.
35. Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478-83.
36. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 2000;24:211-22.
37. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001;136:383-9.
38. Burkill GJC, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003;226:527-32.
39. Ludwig K, Wilhelm L, Scharlau U, Amtsberg G, Bernhardt J. Laparoscopic-endoscopic rendezvous resection of gastric tumors. Surg Endosc 2001;16:1561-5.
40. Tagaya N, Mikami H, Kogure H, Kubota K, Hosoya Y, Nagai H. Laparoscopic intragastric stapled resection of gastric submucosal tumors located near the esophagogastric junction. Surg Endosc 2002;16:177-9.
41. Rothlin M, Schob O. Laparoscopic wedge resection for benign gastric tumors. Surg Endosc 2001;15:893-5.
42. Mainprize KS, Dehn TC. Laparoscopic management of pseudoachalasia, esophageal diverticulum, and benign esophageal stromal tumor. Dis Esophagus 2001;14:73-5.
43. Shirai H, Takeuchi T, Naka T, et al. Gastrointestinal stromal tumor of the stomach: report of a case. Surg Today 2001;31:346-9.
44. Matsui H, Uyama I, Fujita J, Komori Y, Sugioka A, Hasumi A. Gastrointestinal stromal tumor of the stomach successfully treated by laparoscopic proximal gastrectomy with jejunal interposition. Surg Laparosc Endosc Percutan Tech 2000;10:239-42.
45. Otani Y, Ohgami M, Igarashi N, et al. Laparoscopic wedge resection of gastric submucosal tumors. Surg Laparosc Endosc Percutan Tech 2000;10:19-23.
46. Cheng HL, Lee WJ, Lai IR, Yuan RH, Yu SC. Laparoscopic wedge resection of benign gastric tumor. Hepatogastroenterology 1999;46:2100-4.
47. Cueto J, Vazquez-Frias JA, Castaneda-Leeder P, Baquera-Heredia J, Weber-Sanchez A. Laparoscopic-assisted resection of a bleeding gastrointestinal stromal tumor. JSLS 1999;3:225-8.
48. Wolfsohn DM, Savides TJ, Easter DW, Lyche KD. Laparoscopy-assisted endoscopie removal of a stromal-cell tumor of the stomach. Endoscopy 1997;29:679-82.
49. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-703.
50. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002;3:655-64.
51. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992;215:68-77.
52. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003;90:332-9.
53. Piso P, Schlitt HJ, Klempnauer J. Stromal sarcoma of the stomach: therapeutic considerations. Eur J Surg 2000;166:954-8.
54. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 2000;88:66-74.
55. De Pas T, Casali PG, Toma S, et al. Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas? Oncology 2003;64:186-8.
56. DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001;234:540-7.
57. Tervahartiala P, Halavaara J. Radiology of GIST. Ann Chir Gynaecol 1998;87:291-2.
58. Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey F, Eilber FR. Recurrent gastrointestinal stromal sarcomas. Surg Oncol 2000;9:71-5.
59. Patel SR, Benjamin RS. Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors. Surg Oncol 2000;9:67-70.
60. Bhattacharya R, Rao S, Kowdley KV. Liver involvement in patients with solid tumors of nonhepatic origin. Clin Liver Dis 2002;6:1033-43.
61. Bloomston M, Binitie O, Fraiji E, et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg 2002;68:827-31.
62. Tarazov PG. Transcatheter therapy of gastric cancer metastatic to the liver: preliminary results. J Gastroenterol 2000;35:907-11.
63. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484-95.
64. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
65. Nishida T, Kumano S, Sugiura T, et al. Multidetector CT of high-risk patients with occult gastrointestinal stromal tumors. AJR Am J Roentgenol 2003;180:185-9.
66. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
67. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38(Suppl 5):S60-5.
68. Högenauer C, Langner C, Lipp RW, Höfler G, Krejs GJ, Hinterleitner TA. Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour with exon 11 mutation. Eur J Gastroenterol Hepatol 2003;15:323-7.
69. Verweij J, Casali P, Zalcberg J, et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Proc Am Soc Clin Oncol 2003;22:814.
70. Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 2003;22:814.
71. Eisenberg BL, von Mehren M. Pharmacotherapy of gastrointestinal stromal tumours. Expert Opin Pharmacother 2003;4:869-74.
72. Hohenberger P, Bauer S, Schneider U, et al. Tumor resection following imatinib pretreatment in GI stromal tumors. Proc Am Soc Clin Oncol 2003;22:818.
73. Buemming P, Meis-Kindblom JM, Kindblom L-G, et al. Is there an indication for adjuvant treatment with imatinib mesylate in patients with aggressive gastrointestinal stromal tumors (GISTs)? Proc Am Soc Clin Oncol 2003;22:818.
74. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-72.
75. Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O'Leary TJ. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998;78:1633-6.
76. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:53-60.
77. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999;59:4297-300.
78. Sakurai S, Fukasawa T, Chong JM, Tanaka A, Fukayama M. C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal). Jpn J Cancer Res 1999;90:1321-8.
79. Andersson J, Sjögren H, Meis-Kindblom JM, Stenman G, Åman P, Kindblom L-G. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002;160:15-22.
80. Wardelmann E, Neidt I, Bierhoff E, et al. c-kit Mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol 2002;15:125-36.
81. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002;20:3898-905.
82. Lasota J, Wozniak A, Sarlomo-Rikala M, et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000;157:1091-5.
83. Hirota S, Nishida T, Isozaki K, et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumors. J Pathol 2001;193:505-10.
84. Sakurai S, Oguni S, Hironaka M, Fukayama M, Morinaga S, Saito K. Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese. Jpn J Cancer Res 2001;92:494-8.
85. Heinrich MC, Corless CL, Blanke C, et al. KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs) (abstract). Proc Am Soc Clin Oncol 2002;21:2a.
86. de Silva MVC, Reid R. Gastrointestinal stromal tumors (GIST): c-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatrnib. Pathol Oncol Res 2003;9:13-9.
87. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-20.
88. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.